ClinicalTrials.gg
TerminatedNCT01334892Updated Apr 14, 2015

L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients

A Phase 2/3 interventional study of Cyclosporine Inhalation Solution in Bronchiolitis Obliterans, sponsored by Pari Pharma GmbH. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-14.

Sponsored by Pari Pharma GmbH · Phase 2/3, Interventional, and Prevention

Why this study was terminated
Interim analysis results revealed substantial increase of patient number, with unfeasible study prolongation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Bronchiolitis Obliterans with a site in Germany — none open to participants now, none under way, none of them phase 3. Bronchiolitis Obliterans · Germany.

Enrollment
5th of 11
130 · median 90
Started
2009
the only one that year
Phase 2/3
2 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
2 of 18
Pari Pharma GmbH

Among the 18 studies in Bronchiolitis Obliterans with a site in Germany, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 2/3, and was the 6th registered.

Bronchiolitis Obliterans

82 studies on the registry are indexed under Bronchiolitis Obliterans; 9 are open to participants now.

Browse Bronchiolitis Obliterans studies →

Open to participants now

None of the 18 studies in Bronchiolitis Obliterans with a site in Germany is open now. The open studies under Bronchiolitis Obliterans, anywhere →

Who these studies take

Of the 9 Bronchiolitis Obliterans studies recruiting now, 5 set no upper age limit and 4 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Bronchiolitis Obliterans with a site in Germany as a file.
02

Study summary

Immunosuppression is a key intervention in patients with solid organ transplant and is usually achieved by combination therapy with systemic CsA or tacrolimus with azathioprine, mycophenolate mofetil (MMF), or corticoids. However, the outcomes after lung transplantation are poor when compared with those after heart, kidney, or liver transplantation, with a survival rate of only 55% for recipients of lung transplants.

Additional application of aerosolised L-CsA should suppress T-cell activation in the lung tissue and subsequently BOS development. The overall purpose of this phase-II/III study is to obtain efficacy and safety data of L-CsA in the prevention of BOS.

Read the detailed description

Preventive therapeutic intervention by L-CsA is primarily aimed to suppress T-lymphocyte suppression and inflammatory responses and secondly to prevent fibrotic effects making it more likely to be effective in early stages of BOS. Early development of BOS, which mostly will not be diagnosed, and acute organ rejections are strongly patho-physiological associated. Prevention of the very early development of chronic rejection by L-CsA post LTX may be the ideal starting point for IMP application.

03

Conditions studied

  • Bronchiolitis Obliterans
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient's written
  2. Received a single lung, bilateral lung or heart/lung transplantation between 6 weeks and 26 weeks prior to first IMP administration.
  3. Male or female, 18 years of age
  4. Capable of self-administration of medications
  5. Capable of understanding the purpose and risk of the clinical trial
  6. Received the following agents and dosages for maintenance therapy:

    1. Tacrolimus and
    2. Mycophenolate mofetil (MMF) 1 to 3 g/day and
    3. Prednisone or any other therapy; tapered down
  7. Female patients with must have a negative urine pregnancy test prior to first IMP administration.
  8. Estimated > 6 month

Exclusion criteria

Exclusion Criteria:

  1. Any previous episode of bronchiolitis obliterans (BO) or bronchiolitis obliterans syndrome (BOS) of grade 1 or higher
  2. Any active invasive bacterial, viral or fungal infection
  3. Received systemic maintenance therapy other than listed in the inclusion criteria
  4. Received any systemic or topical ciclosporin A within
  5. Received any systemic or topical Rosuvastatin
  6. Current mechanical ventilation
  7. Received a lung re-transplantation
  8. Pregnant or breast feeding woman
  9. Has known to ciclosporin A
  10. Has a serum creatinine value of more than 265 µmol/L (3 mg/dL)
  11. Unlikely to comply with visits, inhalation procedures or spirometric measurements
  12. Receipt of an drug within 4 weeks prior to first administration of IMP
  13. Any co-existing medical condition that in the investigator's judgement
  14. Psychiatric disorders or altered mental status
  15. Patient was previously enrolled in the present clinical trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Active comparator
    L-CsA

    Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks

    Drug: Cyclosporine Inhalation Solution

  • Placebo comparator
    L-CsA placebo

    Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)

    Drug: Cyclosporine Inhalation Solution

Interventions

  • DrugCyclosporine Inhalation Solution

    Cyclosporin for inhalation twice daily

06

What researchers measure

Primary outcomes

  1. The primary objective is to compare cumulative BOS-free survival of patients recieving L-CsA or placebo.

    BOS stage 1 and higher is considered as BOS for the primary endpoint.

    Time frame: 2 years

Secondary outcomes

  1. Cumulative mean incidence of BOS 12, 18 and 24 months after first IMP administration

    Further secondary objectives are to compare further efficacy and safety data from L-CsA versus placebo. Evaluation of IMP pharmacokinetic (PK) data in whole blood samples and bronchoalveolar lavage (BAL)are included in the outcome measure. The main safety evaluation is the incidence of treatment-emergent AEs including clinically relevant laboratory parameters and vital signs

    Time frame: 2 years

07

Study locations

1 site
  • PARI Pharma GmbH
    Graefelfing, 82166, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jul 2013 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2011
First posted
Apr 13, 2011
Start
Dec 2009
Primary completionActual
Jul 2013
CompletionActual
Dec 2014
Last update
Apr 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01334892
Lead sponsor
Pari Pharma GmbH
Responsible party
Sponsor
First posted
Apr 13, 2011
Start date
Dec 2009
Primary completion
Jul 2013
Completion
Dec 2014
Last update
Apr 14, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion